- Home
- APP vs AZN Comparison
APP vs AZN Comparison
Compare APP & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APP
- AZN
- Stock Information
- Founded
- APP 2012
- AZN 1992
- Country
- APP United States
- AZN United Kingdom
- Employees
- APP N/A
- AZN N/A
- Industry
- APP EDP Services
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- APP Technology
- AZN Health Care
- Exchange
- APP Nasdaq
- AZN Nasdaq
- Market Cap
- APP 219.7B
- AZN 252.9B
- IPO Year
- APP 2021
- AZN 1993
- Fundamental
- Price
- APP $634.55
- AZN $85.95
- Analyst Decision
- APP Buy
- AZN Strong Buy
- Analyst Count
- APP 21
- AZN 1
- Target Price
- APP $569.05
- AZN N/A
- AVG Volume (30 Days)
- APP 11.1M
- AZN 5.1M
- Earning Date
- APP 11-05-2025
- AZN 11-11-2025
- Dividend Yield
- APP N/A
- AZN 1.79%
- EPS Growth
- APP 198.85
- AZN 28.86
- EPS
- APP 7.03
- AZN 5.31
- Revenue
- APP $5,737,591,000.00
- AZN $56,501,000,000.00
- Revenue This Year
- APP $20.53
- AZN $10.87
- Revenue Next Year
- APP $33.42
- AZN $6.12
- P/E Ratio
- APP $89.88
- AZN $16.18
- Revenue Growth
- APP 78.91
- AZN 15.00
- 52 Week Low
- APP $137.20
- AZN $61.24
- 52 Week High
- APP $745.61
- AZN $86.57
- Technical
- Relative Strength Index (RSI)
- APP 55.27
- AZN 70.21
- Support Level
- APP $545.00
- AZN $72.90
- Resistance Level
- APP $727.49
- AZN $86.57
- Average True Range (ATR)
- APP 38.99
- AZN 1.46
- MACD
- APP -10.31
- AZN 1.08
- Stochastic Oscillator
- APP 44.98
- AZN 95.17
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.